Q3 EPS Estimate for Halozyme Therapeutics Lifted by Analyst

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Research analysts at Zacks Research boosted their Q3 2025 earnings per share estimates for shares of Halozyme Therapeutics in a report released on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings of $1.12 per share for the quarter, up from their previous forecast of $1.11. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $3.80 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q1 2026 earnings at $1.41 EPS.

Several other research analysts have also recently weighed in on HALO. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday. JMP Securities lifted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research report on Friday, November 1st. HC Wainwright increased their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a "buy" rating in a research report on Friday. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, Wells Fargo & Company cut Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and increased their price target for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $61.44.

Halozyme Therapeutics Trading Down 1.8 %

Halozyme Therapeutics stock traded down $0.96 during trading on Friday, reaching $52.80. 2,146,512 shares of the company were exchanged, compared to its average volume of 1,784,019. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The stock's 50 day simple moving average is $50.23 and its two-hundred day simple moving average is $54.00. The company has a market capitalization of $6.72 billion, a P/E ratio of 17.48, a PEG ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 52-week low of $33.15 and a 52-week high of $65.53.

Institutional Investors Weigh In On Halozyme Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Skandinaviska Enskilda Banken AB publ acquired a new stake in Halozyme Therapeutics in the second quarter valued at $49,000. GAMMA Investing LLC raised its position in shares of Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock worth $50,000 after acquiring an additional 350 shares in the last quarter. Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics in the third quarter valued at approximately $57,000. FSC Wealth Advisors LLC purchased a new position in Halozyme Therapeutics in the third quarter valued at approximately $65,000. Finally, Park Place Capital Corp lifted its position in shares of Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company's stock worth $78,000 after buying an additional 1,209 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 43,611 shares of the company's stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 2.70% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.